The NIH Clinical Center — The "House of Hope"

Dear Colleagues: The main NIH campus, located in Bethesda, Maryland, is home to thousands of scientists spread throughout more than 50 buildings. Most prominent is the Clinical Center , the world’s largest hospital dedicated to clinical research. Known as Building 10, some refer to it as the "House of Hope." It’s been the birthplace of many "firsts": cancer patients received the first chemotherapy to treat tumors, scientists performed the first human gene therapy tests, surgeons first successfully replaced the heart’s mitral valve, and researchers found early success with the first anti-viral drug for HIV/AIDS. This world-renowned facility is currently featured

NIAMS Awards Four Supplements to Advance Research (STAR) From Projects to Programs — Enhancing NIH Support for Early Established Investigators

Overview of the STAR Awards: The NIAMS STAR program provides supplemental funding for early-established investigators who have renewed their first NIAMS-funded R01 grant. The supplement enables these scientists to pursue innovative and high-risk research within the broader scope of a current NIAMS-funded, peer-reviewed research project. It also helps investigators to expand a single, structured research project into a broader multi-faceted research program. In 2017, four investigators received NIAMS STAR supplements. Previously, NIAMS funded three STAR awards in 2015 and five in 2016 . 2017 STAR Awardee Profiles: Karen Costenbader, M.D., M.P.H. , is an associate professor of medicine at Harvard

Sharing Your Scientific Imagery

Dear NIAMS Grantee: Compelling, eye-catching images can communicate the results and impact of scientific research in powerful ways that go beyond words. These days, you rarely see a news story or social media post that does not include an image to draw the reader into the story. Beginning in 2014, we have invited NIAMS-supported researchers to submit images for use in our various communication channels to highlight the outstanding work being done. The community’s response has been extraordinary. I want to issue a new call for scientific images to capture the innovative advances that you have generated in the past

Honoring Health — We Have the Power To Fight Diabetes! — August 2017

*/ /*--> */ /*--> */ /*--> */ We Have the Power To Fight Diabetes! Diabetes is one of the leading causes of death in the United States. It is associated with serious complications, such as heart disease and stroke, blindness, kidney failure and lower limb amputation. The good news is that type 2 diabetes can be delayed or even prevented. Whether you are a health care provider, community representative or a health educator, you have an important role to play when it comes to diabetes education and support. This issue, featuring information to help people living with or at risk

Genetic Evidence Separates Systemic Juvenile Idiopathic Arthritis from Others in Juvenile Idiopathic Arthritis Family

One form of juvenile idiopathic arthritis may need to be reclassified based on the results of a research effort led by the NIH’s National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Genetic analysis suggests that systemic juvenile idiopathic arthritis (sJIA) is distinct from the other forms of juvenile idiopathic arthritis (JIA) and will require a different approach to finding treatment options. The study appeared in the Annals of Rheumatic Diseases . Michael Ombrello, M.D., head of the Translational Genetics and Genomics Unit in the Intramural Research Program at NIAMS, led an international research collaboration to study genetic risk

Genetically Modified Skin Grafts Show Promise For Treating Epidermolysis Bullosa

Researchers have shown early success creating genetically modified skin tissue to graft onto patients with a severe form of epidermolysis bullosa (EB). Stanford University Medical Center scientists conducted a phase 1 clinical trial of four adult patients who have the inherited disease, a devastating condition called recessive dystrophic EB, which causes extensive, painful blisters and skin wounds. Results of the work, which were partly supported by the NIH’s National Institute of Arthritis and Musculoskeletal and Skin Diseases, appeared recently in the Journal of the American Medical Association . The research team took skin biopsies from patients living with recessive dystrophic

Deputy Director’s Letter: Progress in Accelerating New Therapies for Rheumatoid Arthritis and Lupus

In 2014, the NIH, along with the Foundation for the NIH and partners from industry, non-profit organizations, and academia, launched the Accelerating Medicines Partnership (AMP), a five-year research initiative dedicated to identifying promising targets for drug development. The partnership focused on three disease areas—Alzheimer’s disease, type 2 diabetes, and the autoimmune diseases rheumatoid arthritis (RA) and lupus. The goal for the AMP in RA and Lupus (AMP RA/SLE) , which at the NIH is being supported by the NIAMS and the National Institute of Allergy and Infectious Diseases, is to understand the molecular and cellular mechanisms that cause these diseases.

Immune Reaction at Mucosal Sites Signals Rheumatoid Arthritis Initiation

Distinct changes to the immune system precede the onset of rheumatoid arthritis (RA), according to a new study funded in part by the NIH’s National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). The data revealed elevated levels of an antibody-producing cell type found in mucosal areas such as the mouth, lungs and intestinal tract in people at high risk of developing the disease. The findings, which appeared in Arthritis and Rheumatology , represent a step toward understanding how RA begins and may lead to novel strategies for halting its progression. RA is a chronic disease in which the
Subscribe to